NEIL L. BERINSTEIN, M.D. was appointed Chief Scientific Officer in January 2010. Dr. Berinstein, a global pioneer in cancer vaccines, worked with IRX as a consultant prior to his appointment. Prior to joining IRX, Dr. Berinstein served as Assistant Vice President and Global Program Leader at sanofi pasteur where he was in charge of leading the development of sanofi's cancer vaccines both strategically and operationally. Dr. Berinstein was responsible for interacting with international collaborators and leading researchers who were collaborating with sanofi pasteur either at pre-clinical or clinical levels. He saw to completion several multi-center phase I and phase II studies in Canada and the U.S. in colorectal and melanoma projects.

Dr. Berinstein currently holds multiple academic and professional positions, including Professor in the department of medicine, University of Toronto, and Active staff at the Odette Cancer Center of the Sunnybrook Health Science Center. He was the vice-president of the Cancer Vaccine Consortium sponsored by the Sabin Institute and more recently is part of the executive steering committee of the Cancer Research Institute (CRI)-sponsored Cancer Vaccine Consortium. He was formerly a member and leader of the scientific review committee of the Leukemia Research Fund.

Dr. Berinstein is the recipient of numerous grants in his research career and has published 6 book chapters, and over 100 peer-reviewed, invited or review papers to date. He received his pre-medical degree and Medical Doctorate from University of Manitoba and further specialty and research training at the University of Toronto and Stanford University.